See more : Orphazyme A/S (ORPH) Income Statement Analysis – Financial Results
Complete financial analysis of Immix Biopharma, Inc. (IMMX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immix Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NeutriSci International Inc. (NRXCF) Income Statement Analysis – Financial Results
- Brim hf. (BRIM.IC) Income Statement Analysis – Financial Results
- Pentokey Organy (India) Limited (PNTKYOR.BO) Income Statement Analysis – Financial Results
- Balchem Corporation (BCPC) Income Statement Analysis – Financial Results
- transcosmos inc. (TRCLF) Income Statement Analysis – Financial Results
Immix Biopharma, Inc. (IMMX)
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | -89.52M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.47K | 2.14K | 2.47K | 2.32K | 1.08K |
| Gross Profit | -5.47K | -89.52M | -2.47K | -2.32K | -1.08K |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.74M | 4.20M | 126.53K | 248.15K | 583.16K |
| General & Administrative | 7.41M | 4.02M | 1.23M | 205.70K | 259.34K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.41M | 4.02M | 1.23M | 205.70K | 259.34K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 512.00 | 224.00 |
| Operating Expenses | 16.14M | 8.22M | 1.35M | 453.85K | 842.50K |
| Cost & Expenses | 16.14M | 8.22M | 1.35M | 453.85K | 842.50K |
| Interest Income | 572.01K | 0.50 | 179.85 | 101.98 | 109.98 |
| Interest Expense | 0.00 | 497.00 | 179.85K | 101.98K | 109.98K |
| Depreciation & Amortization | 5.47K | 2.14K | 2.47K | 2.32K | 1.08K |
| EBITDA | -16.14M | -8.22M | -1.35M | -451.53K | -841.20K |
| EBITDA Ratio | 0.00% | 9.18% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.14M | -8.22M | -1.35M | -453.85K | -842.50K |
| Operating Income Ratio | 0.00% | 9.18% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 572.01K | -497.00 | -23.03M | -676.46K | -109.76K |
| Income Before Tax | -15.57M | -8.22M | -24.38M | -1.13M | -952.26K |
| Income Before Tax Ratio | 0.00% | 9.18% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 26.42K | 10.27K | 6.01K | 17.55K | 20.55K |
| Net Income | -15.43M | -8.23M | -24.38M | -1.15M | -972.81K |
| Net Income Ratio | 0.00% | 9.19% | 0.00% | 0.00% | 0.00% |
| EPS | -0.89 | -0.62 | -1.84 | -0.15 | -0.29 |
| EPS Diluted | -0.89 | -0.62 | -1.84 | -0.15 | -0.29 |
| Weighted Avg Shares Out | 17.34M | 13.23M | 13.23M | 7.77M | 3.38M |
| Weighted Avg Shares Out (Dil) | 17.34M | 13.23M | 13.23M | 7.77M | 3.38M |
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix...
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses in prior clinical studies Lead site Memorial Sloan Kettering...
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark...
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Data from ex-U.S. clinical trial reported at ASGCT 2024 showed a...
What Makes Immix Biopharma (IMMX) a New Buy Stock
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been...
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at...
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75%...
Source: https://incomestatements.info
Category: Stock Reports